$APLS
Apellis Pharmaceuticals, Inc.

2022 Q4 Form 10-Q Financial Statement

#000095017022022606 Filed on November 07, 2022

View on sec.gov

Income Statement

Concept 2022 Q4 2022 Q3 2021 Q3
Revenue $22.66M $22.06M $5.650M
YoY Change -62.41% 290.37% 774.61%
Cost Of Revenue $2.925M $1.381M $149.0K
YoY Change -42.09% 826.85%
Gross Profit $19.74M $20.68M $5.501M
YoY Change -64.27% 275.84%
Gross Profit Margin 87.09% 93.74% 97.36%
Selling, General & Admin $84.37M $78.41M $74.18M
YoY Change 20.1% 5.69% 30.15%
% of Gross Profit 427.44% 379.23% 1348.55%
Research & Development $99.42M $95.21M $87.73M
YoY Change 33.65% 8.52% -5.87%
% of Gross Profit 503.71% 460.49% 1594.86%
Depreciation & Amortization $388.0K $401.0K $282.0K
YoY Change 4.02% 42.2% 48.42%
% of Gross Profit 1.97% 1.94% 5.13%
Operating Expenses $183.8M $175.0M $133.6M
YoY Change 27.07% 30.94% 2.65%
Operating Profit -$164.1M -$152.9M -$128.1M
YoY Change 83.5% 19.35% -1.09%
Interest Expense -$3.163M -$5.094M -$6.357M
YoY Change -94.56% -19.87% 4.21%
% of Operating Profit
Other Income/Expense, Net -$246.0K $99.00K -$117.0K
YoY Change 6050.0% -184.62% 631.25%
Pretax Income -$167.5M -$190.8M -$195.6M
YoY Change 13.47% -2.43% 44.12%
Income Tax -$1.471M $400.0K $0.00
% Of Pretax Income
Net Earnings -$166.0M -$191.3M -$195.6M
YoY Change 12.21% -2.2% 44.12%
Net Earnings / Revenue -732.43% -867.2% -3461.43%
Basic Earnings Per Share -$1.75 -$2.28
Diluted Earnings Per Share -$1.50 -$1.75 -$2.283M
COMMON SHARES
Basic Shares Outstanding 110.6M 109.9M 85.66K
Diluted Shares Outstanding 109.1K 85.66K

Balance Sheet

Concept 2022 Q4 2022 Q3 2021 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $551.8M $708.6M $430.3M
YoY Change -21.23% 64.66% -40.91%
Cash & Equivalents $551.8M $584.2M $283.7M
Short-Term Investments $0.00 $124.4M $146.6M
Other Short-Term Assets $36.66M $23.93M $39.92M
YoY Change -48.13% -40.06% 181.11%
Inventory $85.71M $59.75M $1.677M
Prepaid Expenses $36.35M $30.36M
Receivables $7.700M $8.100M $3.500M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $719.5M $831.9M $475.4M
YoY Change -12.68% 74.99% -35.95%
LONG-TERM ASSETS
Property, Plant & Equipment $6.148M $5.681M $27.44M
YoY Change -0.47% -79.3% 9.32%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $15.80M $15.75M $22.82M
YoY Change -50.07% -30.98% 2435.89%
Total Long-Term Assets $40.69M $40.96M $50.26M
YoY Change -29.5% -18.52% 93.32%
TOTAL ASSETS
Total Short-Term Assets $719.5M $831.9M $475.4M
Total Long-Term Assets $40.69M $40.96M $50.26M
Total Assets $760.2M $872.9M $525.7M
YoY Change -13.78% 66.05% -31.58%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $37.34M $14.10M $4.984M
YoY Change 120.84% 182.89% -55.1%
Accrued Expenses $95.14M $79.78M $69.85M
YoY Change -7.85% 14.22% 14.94%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $29.50M $16.15M $15.33M
YoY Change 289.03% 5.3%
Total Short-Term Liabilities $167.6M $115.4M $94.24M
YoY Change 27.12% 22.51% 25.15%
LONG-TERM LIABILITIES
Long-Term Debt $408.4M $432.8M $189.6M
YoY Change -23.55% 128.26% -46.41%
Other Long-Term Liabilities $14.35M $1.938M $299.2M
YoY Change -15.98% -99.35% 28.12%
Total Long-Term Liabilities $422.7M $1.938M $488.8M
YoY Change -23.31% -99.6% -16.78%
TOTAL LIABILITIES
Total Short-Term Liabilities $167.6M $115.4M $94.24M
Total Long-Term Liabilities $422.7M $1.938M $488.8M
Total Liabilities $590.3M $565.5M $583.0M
YoY Change -13.58% -3.01% -12.0%
SHAREHOLDERS EQUITY
Retained Earnings -$2.300B -$2.143B
YoY Change 38.83%
Common Stock $11.00K $11.00K
YoY Change 10.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $169.9M $307.4M -$57.33M
YoY Change
Total Liabilities & Shareholders Equity $760.2M $872.9M $525.7M
YoY Change -13.78% 66.05% -31.58%

Cashflow Statement

Concept 2022 Q4 2022 Q3 2021 Q3
OPERATING ACTIVITIES
Net Income -$166.0M -$191.3M -$195.6M
YoY Change 12.21% -2.2% 44.12%
Depreciation, Depletion And Amortization $388.0K $401.0K $282.0K
YoY Change 4.02% 42.2% 48.42%
Cash From Operating Activities -$140.7M -$154.4M -$168.6M
YoY Change 25.11% -8.43% 68.91%
INVESTING ACTIVITIES
Capital Expenditures $851.0K -$196.0K -$352.0K
YoY Change -4578.95% -44.32% -90.59%
Acquisitions
YoY Change
Other Investing Activities $125.0M $125.0M $180.0M
YoY Change 47.04% -30.57% -11.11%
Cash From Investing Activities $124.1M $124.8M $179.6M
YoY Change 46.07% -30.54% -9.62%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -15.95M 9.636M 2.120M
YoY Change -104.15% 354.53% 130.43%
NET CHANGE
Cash From Operating Activities -140.7M -154.4M -168.6M
Cash From Investing Activities 124.1M 124.8M 179.6M
Cash From Financing Activities -15.95M 9.636M 2.120M
Net Change In Cash -32.56M -20.00M 13.14M
YoY Change -109.14% -252.14% -86.84%
FREE CASH FLOW
Cash From Operating Activities -$140.7M -$154.4M -$168.6M
Capital Expenditures $851.0K -$196.0K -$352.0K
Free Cash Flow -$141.6M -$154.2M -$168.3M
YoY Change 25.88% -8.35% 75.12%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
6273000
apls Operating Cost Of Sales
OperatingCostOfSales
149000
us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
apls Minimum Percentage Of Tax Position Likelihood Of Being Realized Upon Examination By Taxing Authorities
MinimumPercentageOfTaxPositionLikelihoodOfBeingRealizedUponExaminationByTaxingAuthorities
0.50
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
apls Operating Lease Right Of Use Asset And Right Of Use Liability Amortization Expense Reversal
OperatingLeaseRightOfUseAssetAndRightOfUseLiabilityAmortizationExpenseReversal
110000
us-gaap Depreciation
Depreciation
1164000
us-gaap Depreciation
Depreciation
1006000
apls Amortization Of Discounts For Convertible Notes Net Of Financing Costs
AmortizationOfDiscountsForConvertibleNotesNetOfFinancingCosts
386000
apls Amortization Of Discounts For Convertible Notes Net Of Financing Costs
AmortizationOfDiscountsForConvertibleNotesNetOfFinancingCosts
821000
CY2022Q3 us-gaap Assets
Assets
872892000
CY2021Q4 us-gaap Assets
Assets
881765000
CY2022Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
14099000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
16909000
CY2022Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
79778000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
103239000
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Entity Central Index Key
EntityCentralIndexKey
0001492422
dei Amendment Flag
AmendmentFlag
false
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
CY2021Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-38276
dei Entity Registrant Name
EntityRegistrantName
APELLIS PHARMACEUTICALS, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
27-1537290
dei Entity Address Address Line1
EntityAddressAddressLine1
100 Fifth Avenue
dei Entity Address City Or Town
EntityAddressCityOrTown
Waltham
dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02451
dei City Area Code
CityAreaCode
617
dei Local Phone Number
LocalPhoneNumber
977-5700
dei Security12b Title
Security12bTitle
Common Stock, $0.0001 par value per share
CY2022Q3 apls Development Liability Current
DevelopmentLiabilityCurrent
16146000
CY2021Q4 apls Development Liability Current
DevelopmentLiabilityCurrent
7584000
CY2022Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
110575547
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
584189000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
640192000
CY2022Q3 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
124364000
CY2021Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
60358000
CY2022Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
8091000
CY2021Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
10103000
CY2022Q3 us-gaap Inventory Net
InventoryNet
59753000
CY2021Q4 us-gaap Inventory Net
InventoryNet
16286000
CY2022Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
30356000
CY2021Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
24868000
CY2022Q3 us-gaap Restricted Cash Current
RestrictedCashCurrent
1259000
CY2022Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
5423000
CY2021Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
1563000
CY2022Q3 us-gaap Other Assets Current
OtherAssetsCurrent
23925000
CY2021Q4 us-gaap Other Assets Current
OtherAssetsCurrent
70677000
CY2022Q3 us-gaap Assets Current
AssetsCurrent
831937000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
824047000
CY2022Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
19522000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
19901000
dei Trading Symbol
TradingSymbol
APLS
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
CY2022Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
5681000
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-2142869000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
6177000
CY2022Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
15752000
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
31640000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
4115000
CY2022Q3 us-gaap Liabilities Current
LiabilitiesCurrent
115446000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
131847000
CY2022Q3 apls Development Liability Noncurrent
DevelopmentLiabilityNoncurrent
340142000
CY2021Q4 apls Development Liability Noncurrent
DevelopmentLiabilityNoncurrent
345151000
CY2022Q3 us-gaap Convertible Debt Noncurrent
ConvertibleDebtNoncurrent
92663000
CY2021Q4 us-gaap Convertible Debt Noncurrent
ConvertibleDebtNoncurrent
189024000
CY2022Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
15287000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
17081000
CY2022Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1938000
CY2022Q3 us-gaap Liabilities
Liabilities
565476000
CY2021Q4 us-gaap Liabilities
Liabilities
683103000
CY2022Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2022Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q3 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2022Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2022Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
110476000
CY2022Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
110476000
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
97524000
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
97524000
CY2022Q3 us-gaap Common Stock Value
CommonStockValue
11000
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
10000
CY2022Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
2453301000
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
1857430000
CY2022Q3 apls Operating Cost Of Sales
OperatingCostOfSales
1381000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-42000
CY2021Q3 apls Operating Cost Of Sales
OperatingCostOfSales
149000
apls Operating Cost Of Sales
OperatingCostOfSales
2711000
CY2022Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-3027000
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-2090000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1366000
CY2022Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-190823000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1656688000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
307416000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
198662000
CY2022Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
872892000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
881765000
CY2022Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
22056000
CY2021Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
5650000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
52759000
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
95207000
CY2021Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
87733000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
287813000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
267688000
apls Cost Of Research Collaboration
CostOfResearchCollaboration
50000000
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
78406000
CY2021Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
45763000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
192795000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
135309000
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
174994000
CY2021Q3 us-gaap Operating Expenses
OperatingExpenses
133645000
us-gaap Operating Expenses
OperatingExpenses
483319000
us-gaap Operating Expenses
OperatingExpenses
453146000
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-152938000
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-127995000
us-gaap Operating Income Loss
OperatingIncomeLoss
-430560000
us-gaap Operating Income Loss
OperatingIncomeLoss
-446873000
CY2022Q3 apls Loss On Conversion Of Debt
LossOnConversionOfDebt
32890000
CY2021Q3 apls Loss On Conversion Of Debt
LossOnConversionOfDebt
61102000
apls Loss On Conversion Of Debt
LossOnConversionOfDebt
32890000
apls Loss On Conversion Of Debt
LossOnConversionOfDebt
100589000
CY2021Q3 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
-4219000
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
-42483000
CY2022Q3 us-gaap Investment Income Nonoperating
InvestmentIncomeNonoperating
2809000
CY2021Q3 us-gaap Investment Income Nonoperating
InvestmentIncomeNonoperating
144000
us-gaap Investment Income Nonoperating
InvestmentIncomeNonoperating
4339000
us-gaap Investment Income Nonoperating
InvestmentIncomeNonoperating
381000
CY2022Q3 apls Interest Expense Nonoperating
InterestExpenseNonoperating
7903000
CY2021Q3 apls Interest Expense Nonoperating
InterestExpenseNonoperating
2282000
apls Interest Expense Nonoperating
InterestExpenseNonoperating
24888000
apls Interest Expense Nonoperating
InterestExpenseNonoperating
10223000
CY2022Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
99000
CY2021Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-117000
CY2021Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-156000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-554000
CY2021Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-195571000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-1912000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-484041000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-598421000
CY2022Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
4770000
CY2022Q2 us-gaap Restricted Stock Value Shares Issued Net Of Tax Withholdings
RestrictedStockValueSharesIssuedNetOfTaxWithholdings
-536000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
22530000
CY2022Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
446000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
2140000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-191269000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-195571000
us-gaap Net Income Loss
NetIncomeLoss
-486181000
us-gaap Net Income Loss
NetIncomeLoss
-598421000
CY2022Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
435000
CY2021Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-25000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-383000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
19000
CY2022Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-268000
CY2022Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
167000
CY2021Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-181000
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-937000
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-1893000
CY2022Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-191102000
CY2021Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-195752000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-487118000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-600314000
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.75
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.75
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.28
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.28
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-4.65
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-4.65
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-7.31
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-7.31
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
109126
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
109126
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
85661
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
85661
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
104608
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
104608
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
81846
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
81846
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
198662000
CY2022Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
380120000
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
4000000
CY2022Q1 us-gaap Restricted Stock Value Shares Issued Net Of Tax Withholdings
RestrictedStockValueSharesIssuedNetOfTaxWithholdings
-2416000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
20773000
CY2022Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-52000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-138935000
CY2022Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
83000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
462235000
CY2022Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
2531000
CY2022Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-766000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-155977000
CY2022Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-369000
apls Accretion Of Discount To Development Liability
AccretionOfDiscountToDevelopmentLiability
20053000
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
1938000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-2010000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
334418000
CY2022Q3 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
129636000
CY2022Q3 apls Adjustments To Additional Paid In Capital Forfeiture Of Accrued Interest In Exchange Of Convertible Notes
AdjustmentsToAdditionalPaidInCapitalForfeitureOfAccruedInterestInExchangeOfConvertibleNotes
1287000
CY2022Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
10639000
CY2022Q3 us-gaap Restricted Stock Value Shares Issued Net Of Tax Withholdings
RestrictedStockValueSharesIssuedNetOfTaxWithholdings
-1003000
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
23541000
CY2022Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
435000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-191269000
CY2022Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-268000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
307416000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
204557000
CY2021Q1 apls Accounting Standards Update Description
AccountingStandardsUpdateDescription
ASU 2020-06
CY2021Q1 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
162258000
CY2021Q1 apls Adjustments To Additional Paid In Capital Forfeiture Of Accrued Interest In Exchange Of Convertible Notes
AdjustmentsToAdditionalPaidInCapitalForfeitureOfAccruedInterestInExchangeOfConvertibleNotes
1668000
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
2588000
CY2021Q1 us-gaap Restricted Stock Value Shares Issued Net Of Tax Withholdings
RestrictedStockValueSharesIssuedNetOfTaxWithholdings
-956000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
16439000
CY2021Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
79000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-183659000
CY2021Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-1582000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
51658000
CY2021Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
7062000
CY2021Q2 us-gaap Restricted Stock Value Shares Issued Net Of Tax Withholdings
RestrictedStockValueSharesIssuedNetOfTaxWithholdings
-233000
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
17722000
CY2021Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
1698000
CY2021Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-35000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-219191000
CY2021Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-174000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
-141493000
CY2021Q3 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
258105000
CY2021Q3 apls Adjustments To Additional Paid In Capital Forfeiture Of Accrued Interest In Exchange Of Convertible Notes
AdjustmentsToAdditionalPaidInCapitalForfeitureOfAccruedInterestInExchangeOfConvertibleNotes
2503000
CY2021Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
2480000
CY2021Q3 us-gaap Restricted Stock Value Shares Issued Net Of Tax Withholdings
RestrictedStockValueSharesIssuedNetOfTaxWithholdings
-362000
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
17194000
CY2021Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-25000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-195571000
CY2021Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-156000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
-57325000
us-gaap Profit Loss
ProfitLoss
-486181000
us-gaap Profit Loss
ProfitLoss
-598421000
us-gaap Share Based Compensation
ShareBasedCompensation
66844000
us-gaap Share Based Compensation
ShareBasedCompensation
51355000
apls Loss On Conversion Of Debt
LossOnConversionOfDebt
32890000
apls Loss On Conversion Of Debt
LossOnConversionOfDebt
100589000
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
-42483000
apls Forfeiture Of Accrued Interest In Exchange Of Convertible Notes
ForfeitureOfAccruedInterestInExchangeOfConvertibleNotes
1287000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
2618000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
43436000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
1677000
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
5492000
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
5862000
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
-45457000
apls Forfeiture Of Accrued Interest In Exchange Of Convertible Notes
ForfeitureOfAccruedInterestInExchangeOfConvertibleNotes
4171000
apls Operating Lease Right Of Use Asset And Right Of Use Liability Amortization Expense Reversal
OperatingLeaseRightOfUseAssetAndRightOfUseLiabilityAmortizationExpenseReversal
-105000
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
268300000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
171280000
us-gaap Nature Of Operations
NatureOfOperations
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1. Nature of Organization and Operations</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Apellis Pharmaceuticals, Inc. (the “Company”) is a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company was incorporated in September 2009 under the laws of the State of Delaware. The Company’s principal executive offices are located in Waltham, Massachusetts.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company’s operations since inception have been limited to organizing and staffing the Company, acquiring rights to product candidates, business planning, raising capital, developing its product candidates, and commercializing EMPAVELI (pegcetacoplan) for the treatment of paroxysmal nocturnal hemoglobinuria (“PNH”).</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company is subject to risks common in the biotechnology industry including, but not limited to, raising additional capital, development by its competitors of new technological innovations, its ability to successfully complete preclinical and clinical development of product candidates and receive timely regulatory approval of products, market acceptance of the Company’s products, protection of proprietary technology, healthcare cost containment initiatives, and compliance with governmental regulations, including those of the U.S. Food and Drug Administration (“FDA”).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Liquidity and Going Concern</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The accompanying unaudited condensed consolidated financial statements have been prepared on the basis of the realization of assets and the satisfaction of liabilities and commitments in the normal course of business. As of November 7, 2022, the date of issuance of these unaudited condensed consolidated financial statements, the Company believes that its cash and cash equivalents and marketable securities of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">708.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> as of September 30, 2022 will be sufficient to fund its operations and capital expenditures for at least the next twelve months. The Company’s future viability beyond that point is dependent on its ability to raise additional capital to finance its operations.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">There are uncertainties associated with the Company’s ability to (1) obtain additional debt or equity financing on terms that are favorable to the Company, (2) enter into collaborative agreements with strategic partners, and (3) succeed in its future operations. If the Company is not able to obtain the required funding for its operations or is not able to obtain funding on terms that are favorable to the Company, it could be forced to delay, reduce or eliminate its research and development programs or future commercialization efforts and its business could be materially harmed.</span></p>
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
-6677000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-15885000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
3956000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-4437000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-3213000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-21264000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-42092000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-373001000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-450627000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
673000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1084000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
331863000
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
335000000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-64236000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
162636000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
380120000
apls Proceeds From Payments For Development Derivative Liability
ProceedsFromPaymentsForDevelopmentDerivativeLiability
-4000000
apls Payments For Development Liability
PaymentsForDevelopmentLiability
16500000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
19409000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
12131000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
2531000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
1698000
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
3955000
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
1551000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
381605000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
8278000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-675000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-2024000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-56307000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-281737000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
641755000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
567045000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
585448000
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
285308000
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
584189000
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
283745000
CY2022Q3 us-gaap Restricted Cash
RestrictedCash
1259000
CY2021Q3 us-gaap Restricted Cash
RestrictedCash
1563000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
585448000
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
285308000
us-gaap Interest Paid Net
InterestPaidNet
5003000
us-gaap Interest Paid Net
InterestPaidNet
10265000
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
156000
us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
98086000
us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
327276000
CY2022Q3 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
1900000
CY2022Q3 apls Cash And Cash Equivalents And Marketable Securities
CashAndCashEquivalentsAndMarketableSecurities
708600000
us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results may differ from those estimates. Management considers many factors in selecting appropriate financial accounting policies and controls, and in developing the estimates and assumptions that are used in the preparation of these financial statements. Management must apply significant judgment in this process. In addition, other factors may affect estimates, including expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates, and whether historical trends are expected to be representative of future trends. The estimation process often may yield a range of potentially reasonable estimates of the ultimate future outcomes, and management must select an amount that falls within that range of reasonable estimates. Estimates are used in the following areas, among others: development derivative liability, accrued expenses, prepaid expenses, convertible debt and taxes.</span></p>
CY2022Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
8100000
CY2021Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
10100000
CY2022Q3 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
300000
CY2021Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
200000
CY2022Q3 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
723000
CY2022Q3 apls Accrued Payroll Liabilities Current
AccruedPayrollLiabilitiesCurrent
33467000
CY2021Q4 apls Accrued Payroll Liabilities Current
AccruedPayrollLiabilitiesCurrent
25212000
CY2022Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
17517000
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
12810000
CY2022Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
79778000
CY2022Q3 us-gaap Inventory Raw Materials
InventoryRawMaterials
25955000
CY2021Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
5749000
CY2022Q3 us-gaap Inventory Work In Process
InventoryWorkInProcess
33124000
CY2021Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
10058000
CY2022Q3 us-gaap Inventory Finished Goods
InventoryFinishedGoods
674000
CY2021Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
479000
CY2022Q3 us-gaap Inventory Net
InventoryNet
59753000
CY2021Q4 us-gaap Inventory Net
InventoryNet
16286000
CY2022Q3 apls Prepaid Research And Development Cost Current
PrepaidResearchAndDevelopmentCostCurrent
16000000.0
CY2021Q4 apls Prepaid Research And Development Cost Current
PrepaidResearchAndDevelopmentCostCurrent
12000000.0
CY2022Q3 apls Accrued Research And Development Current
AccruedResearchAndDevelopmentCurrent
28071000
CY2021Q4 apls Accrued Research And Development Current
AccruedResearchAndDevelopmentCurrent
35217000
CY2021Q4 apls Accrued Cost Of Research Collaborations Current
AccruedCostOfResearchCollaborationsCurrent
25000000
CY2021Q4 apls Accrued License Fees Current
AccruedLicenseFeesCurrent
5000000
CY2022Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
3134000
CY2022Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
20710000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
103239000
us-gaap Litigation Settlement Amount Awarded To Other Party
LitigationSettlementAmountAwardedToOtherParty
0
CY2020Q4 apls Development Derivative Liabilities Gross
DevelopmentDerivativeLiabilitiesGross
257868000
CY2021Q1 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
-17084000
CY2021Q1 apls Development Derivative Liabilities Gross
DevelopmentDerivativeLiabilitiesGross
274952000
CY2021Q2 apls Minimum Payment Of Additional Funding Amount
MinimumPaymentOfAdditionalFundingAmount
-4000000
CY2021Q2 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
-21180000
CY2021Q2 apls Development Derivative Liabilities Gross
DevelopmentDerivativeLiabilitiesGross
292132000
CY2021Q3 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
-4219000
CY2021Q3 apls Development Derivative Liabilities Gross
DevelopmentDerivativeLiabilitiesGross
296351000
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
-42500000
us-gaap Lessee Operating Lease Description
LesseeOperatingLeaseDescription
The Company enters into lease agreements with terms generally ranging from 2-7 years. Some of the Company’s lease agreements include Company options to extend the lease on a month-to-month basis or for set periods for up to five years. Many of these leases also include options to terminate the leases within one year or per other contractual terms. Renewal and termination options were generally not included in the lease term for the Company’s existing operating leases.
us-gaap Lessee Operating Lease Existence Of Option To Extend
LesseeOperatingLeaseExistenceOfOptionToExtend
true
apls Lessee Operating Lease Maximum Term Of Options To Terminate Lease
LesseeOperatingLeaseMaximumTermOfOptionsToTerminateLease
P1Y
CY2021Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
23844000
CY2022Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
19522000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
19901000
CY2022Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
20710000
CY2021Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
21196000
CY2022Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P3Y9M14D
CY2021Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P4Y7M28D
CY2022Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0732
CY2021Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0771
CY2022Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
1700000
CY2021Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
1400000
us-gaap Operating Lease Cost
OperatingLeaseCost
4600000
us-gaap Operating Lease Cost
OperatingLeaseCost
4200000
us-gaap Operating Lease Payments
OperatingLeasePayments
5499000
us-gaap Operating Lease Payments
OperatingLeasePayments
4476000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
5675000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
1669000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
6673000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
5913000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
4750000
CY2022Q3 apls Lessee Operating Lease Liability Payments Due Year Four And Thereafter
LesseeOperatingLeaseLiabilityPaymentsDueYearFourAndThereafter
4839000
CY2022Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
400000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
2100000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
18458
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
18909

Files In Submission

Name View Source Status
0000950170-22-022606-index-headers.html Edgar Link pending
0000950170-22-022606-index.html Edgar Link pending
0000950170-22-022606.txt Edgar Link pending
0000950170-22-022606-xbrl.zip Edgar Link pending
apls-20220930.htm Edgar Link pending
apls-20220930.xsd Edgar Link pending
apls-ex31_1.htm Edgar Link pending
apls-ex31_2.htm Edgar Link pending
apls-ex32_1.htm Edgar Link pending
apls-ex32_2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
apls-20220930_lab.xml Edgar Link unprocessable
apls-20220930_def.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
apls-20220930_pre.xml Edgar Link unprocessable
apls-20220930_htm.xml Edgar Link completed
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
apls-20220930_cal.xml Edgar Link unprocessable